Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Other Non-Current Assets: 2019-2025

Historic Other Non-Current Assets for Lyell Immunopharma (LYEL) over the last 6 years, with Sep 2025 value amounting to $2.5 million.

  • Lyell Immunopharma's Other Non-Current Assets rose 783.68% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year increase of 783.68%. This contributed to the annual value of $4.6 million for FY2024, which is 9.14% up from last year.
  • Latest data reveals that Lyell Immunopharma reported Other Non-Current Assets of $2.5 million as of Q3 2025, which was up 0.59% from $2.5 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Other Non-Current Assets registered a high of $4.6 million during Q4 2024, and its lowest value of $279,000 during Q1 2022.
  • Moreover, its 3-year median value for Other Non-Current Assets was $288,000 (2024), whereas its average is $1.7 million.
  • As far as peak fluctuations go, Lyell Immunopharma's Other Non-Current Assets plummeted by 40.13% in 2022, and later spiked by 1,412.50% in 2023.
  • Lyell Immunopharma's Other Non-Current Assets (Quarterly) stood at $466,000 in 2021, then slumped by 39.91% to $280,000 in 2022, then skyrocketed by 1,412.50% to $4.2 million in 2023, then grew by 9.14% to $4.6 million in 2024, then spiked by 783.68% to $2.5 million in 2025.
  • Its last three reported values are $2.5 million in Q3 2025, $2.5 million for Q2 2025, and $3.2 million during Q1 2025.